Which infants with chronic lung disease are candidates for palivizumab, and when should it start?
Metadata[+] Show full item record
Palivizumab prophylaxis against respiratory syncytial virus (RSV) bronchiolitis should be considered for infants and children <24 months of age with chronic lung disease (CLD) of prematurity who receive ongoing medical therapy (supplemental oxygen, bronchodilator, diuretic, or chronic corticosteroid therapy) for CLD within 6 months before the start of the RSV season. A monthly intramuscular (IM) injection for 5 doses is usually given beginning November or December in most locations in the United States (SOR: B, RCT and evidence-based guideline).
Evidence Based Practice 15(9): 11.